FDA issues Not Approvable Letter for Novocure’s Optune Mya brain‑metastases device

Novocure received a Not Approvable Letter from the U.S. Food and Drug Administration for its Premarket Approval application for Optune Mya, a device intended to treat adult patients with brain metastases from non‑small cell lung cancer after stereotactic radiation. The agency said the submission lacked sufficient evidence of clinical benefit but did not raise any safety concerns. Novocure said it will review the feedback and meet with the FDA to explore possible pathways that would not require additional clinical trials, while noting that future approval is not guaranteed.

The regulatory rejection triggered an immediate decline in Novocure’s share price, with the stock falling between 2% and 6% in the days following the announcement. The outcome also delays any potential revenue from a new indication that the company had expected to launch by the end of 2026, affecting near‑term growth expectations.

  • 1Novocure received a Not Approvable Letter from the FDA for its Optune Mya Premarket Approval application.
  • 2The FDA cited uncertainty about the degree of clinical benefit as the reason for the denial.
  • 3The agency did not raise any safety concerns regarding Optune Mya.
  • 4Novocure plans to meet with the FDA to discuss options that would not require additional clinical studies, but it cannot guarantee future approval.
  • 5Shares fell 1.99% to $13.28 after the news was released.
  • 6Pre‑market trading showed a 4.07% decline in the stock.
  • Share‑price decline figures differ across sources (1.99%, 4.07%, ~6%).

Sources